Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
March 20 2018 - 8:30AM
Celsion Corporation (NASDAQ: CLSN) announced today that the
Company will host a conference call to discuss financial results
for the year ended December 31, 2017 and provide an update on its
development programs for ThermoDox®, its proprietary heat-activated
liposomal encapsulation of doxorubicin and GEN-1, an IL-12 DNA
plasmid vector formulated into a nanoparticle with a non-viral
delivery system at 11:00 a.m. EDT on Tuesday, March 27, 2018. To
participate in the call, interested parties may dial 1-888-737-3628
(Toll-Free/North America) or 1-719-325-4879 (International/Toll)
and ask for the Celsion Corporation 4th Quarter 2017 Earnings Call
(Conference Code: 1256084) to register ten minutes before the call
is scheduled to begin. The call will also be broadcast live over
the internet at www.celsion.com.
The call will be archived for replay on Tuesday,
March 27, 2018 and will remain available until Tuesday, April 10,
2018. The replay can be accessed at 1-719-457-0820 or
1-719-785-5608 using Conference ID: 1256084. An audio replay
of the call will also be available on the Company’s website,
www.celsion.com, for 90 days after 2:00 p.m. EDT on Tuesday, March
27, 2018.
About Celsion Corporation
Celsion is a fully-integrated oncology company
focused on developing a portfolio of innovative cancer treatments,
including directed chemotherapies, immunotherapies and RNA- or
DNA-based therapies. The Company's lead program is ThermoDox®, a
proprietary heat-activated liposomal encapsulation of doxorubicin,
currently in Phase III development for the treatment of primary
liver cancer and in development for other cancer indications.
The Company’s product pipeline also includes GEN-1, a DNA-based
immunotherapy for the localized treatment of ovarian and brain
cancers. Celsion has two platform technologies for the
development of novel nucleic acid-based immunotherapies and other
anti-cancer DNA or RNA therapies. For more information on Celsion,
visit our website: http://www.celsion.com. (CLSN-FIN).
Celsion Investor Contact
Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024